Trial Profile
A retrospective natural history study of visual function in subjects with inherited retinal disease treated with zuretinol acetate
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Zuretinol acetate (Primary)
- Indications Leber congenital amaurosis; Retinitis pigmentosa
- Focus Therapeutic Use
- 09 May 2017 Results(n=25) published in the Novelion Therapeutics media release.
- 09 May 2017 According to a Novelion Therapeutics media release, data from this trial presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2017.
- 28 Apr 2016 New trial record